Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: A pilot study

Journal of Thoracic and Cardiovascular Surgery

Volumn 144, Issue 5, 2012, Pages 1241-1248

  Sezai, Akira ^a   Nakai, Tishiko ^a   Hata, Mitsumasa ^a   Yoshitake, Isamu ^a   Shiono, Motomi ^a   Kunimoto, Satoshi ^a   Hirayama, Atsushi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; LANDIOLOL; N(G),N(G) DIMETHYLARGININE; PENTRAXIN 3; TROPONIN I; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; FABP3 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; SERUM AMYLOID P; UREA;

AGED; ARTICLE; ATRIAL FIBRILLATION; CLINICAL OUTCOME; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART ATRIUM PACING; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL MORTALITY; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; METABOLISM; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ARGININE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BISOPROLOL; C-REACTIVE PROTEIN; CORONARY ARTERY BYPASS; CREATINE KINASE, MB FORM; DRUG ADMINISTRATION SCHEDULE; FATTY ACID-BINDING PROTEINS; FEMALE; HEMODYNAMICS; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; MORPHOLINES; NATRIURETIC PEPTIDE, BRAIN; PILOT PROJECTS; SERUM AMYLOID P-COMPONENT; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I; UREA;

EID: 85027942780     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.06.042     Document Type: Article

References (26)

1. Villareal, R.P., Hariharan, R., Liu, B.C., Kar, B., Lee, V., Elayda, M., et al. Postoperative atrial fibrillation and mortality after coronary atrial bypass surgery. J Am Col Cardiol 43 (2004), 742–748.
2. Shen, J., Shelly, L., Zheng, V., Buckley, P., Damiano, R.J., Schuessler, R.B., The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades. J Thorac Cardiovasc Surg 141 (2011), 559–570.
3. Sezai, A., Hata, M., Niino, T., Kasamaki, Y., Nakai, T., Hirayama, A., et al. Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. J Thorac Cardiovasc Surg 137 (2009), 895–900.
4. Nakai, T., Lee, R.J., Schiller, N.B., Bellows, Dzankic, S., Reeves, J.R., et al. The relative importance of left atrial function versus dimension in predicting atrial fibrillation after coronary artery bypass graft surgery. Am Heart J 143 (2002), 181–186.
5. Budeus, M., Hennersdorf, M., Perings, S., Roehlen, S., Schnitzler, S., Felix, O., et al. Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blind, placebo-controlled, randomized study. Eur Heart J 27 (2006), 1584–1591.
6. Bramer, S., van Stranten, A.H.M., Hamad, M.A.S., Berrlkouw, E., Martens, E.J., Maessen, J.G., The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting. Ann Thorac Surg 90 (2010), 443–450.
7. El-Chami, M.F., Kilgo, P., Thourani, V., Lattouf, O.M., Delurgio, D.B., Guyton, R.A., et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol 55 (2010), 1370–1376.
8. Kaw, R., Hernandez, A.V., Masood, I., Gillinov, A.M., Saliba, W., Blackstone, E.H., Short- and long-term mortality associated with new-onset atrial fibrillation after coronary artery bypass grafting: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 141 (2011), 1305–1312.
9. Giri, S., White, C.M., Dunn, A.B., Felton, K., Freeman-Bosco, L., Reddy, P., et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the atrial fibrillation suppression trial (AFIST): randomized placebo-controlled trial. Lancet 357 (2001), 830–836.
10. Shen, J., Lall, S., Zheng, V., Buckley, P., Damiano, R.J., Schuessler, R.B., The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades. J Thorac Cardiovasc Surg 141 (2011), 559–570.
11. Chen, W.T., Krishnan, G.M., Sood, N., Kluger, J., Coleman, C.I., Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg 140 (2010), 364–372.
12. Fuster, V., Ryden, L.E., Cannom, D.S., Crijns, H.J., Curtis, A.B., Ellenbogen, K.A., et al. ACC/AHA/ESC 2006 guideline for management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and Heart Rhythm Society. Circulation 114 (2006), e257–e354.
13. Maniar, P.B., Balcetyye-Harris, N., Tamis, J.E., Steinberg, J.S., Intravenous versus oral beta-blockers for prevention of post-CABG atrial fibrillation in high-risk patients identified by signal-averaged ECG: lessons of a pilot study. Card Electrophysiol Rev 7 (2003), 158–161.
14. Mooss, A.N., Wurdeman, R.L., Mohiuddin, E.M., Reyes, A.P., Sugimoto, J.T., Scott, W., et al. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery. Am Heart J 140 (2000), 176–180.
15. Iguchi, S., Iwamura, H., Nishizaki, M., Hayashi, A., Senokuchi, K., Kobayashi, K., et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo) 40 (1992), 1462–1469.
16. Sugiyama, A., Takahara, A., Hashimoto, K., Electrophysiologic cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol 34 (1999), 70–77.
17. Sasao, J., Tarver, S.D., Kindscher, J.D., Taneyama, C., Benson, K.T., Goto, H., In rabbits, landiolol, a new ultra-short-acting β-blocker, exerts a more potent negative chronologic effect and less effect on blood pressure than esmolol. Can J Anesth 48 (2001), 985–989.
18. Sezai, A., Minami, K., Nakai, T., Hata, M., Yoshitake, I., Wakui, S., et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg 141 (2011), 1478–1487.
19. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guideline: developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005), e154–e235.
20. Konishi, M., Haraguchi, G., Kimura, S., Inagaki, H., Kawabata, M., Hachiya, H., et al. Comparative effects of carvedilol vs. bisoprolol for severe congestive heart failure. Circ J 74 (2010), 1127–1134.
21. Marazzi, G., Iellamo, F., Volterrani, M., Caminiti, G., Madonna, M., Arisi, G., et al. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. Am J Cardiol 107 (2011), 215–219.
22. Sleilaty, G., Madi-Jebara, S., Yazigi, A., Haddad, F., Hayeck, G., El Rassi, I., et al. Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial. Int J Cardiol 137 (2009), 116–122.
23. Latini, R., Maggioni, A.P., Peri, G., Gonzini, L., Lucci, D., Mocarelli, P., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110 (2004), 2349–2354.
24. Matusbara, J., Sugiyama, S., Nozaki, T., Sugamura, K., Konishi, M., Ohba, K., et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57 (2011), 861–869.
25. Goette, A., Hammwoehner, M., Bukowska, A., Scalera, F., Martens-Lobenhoffer, J., Dobrev, D., et al. The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 26:154 (2012), 141–146.
26. Xia, W., Yin, Z., Li, J., Song, Y., Qu, X., Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. PACE 32 (2009), 1562–1566.